MedTrace Logo

An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

NCT06883240 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2026-05-15

No results posted yet for this study

Summary

This non-interventional study (NIS) is designed to collect information on the effectiveness and safety of treatment received in routine clinical care, as well as measure the health-related quality of life (HRQoL) of participants with Type 3 von Willebrand disease (VWD) receiving prophylactic therapy per local standard of care (SOC) over an observation period of at least 24 weeks.

Conditions

  • Von Willebrand Disease, Type 3

Interventions

DRUG

Von Willebrand Factor Concentrates

Used according to local labeling or local treatment guidelines.

DRUG

Von Willebrand Factor Concentrates and Factor VIII Concentrates

Used according to local labeling or local treatment guidelines.

DRUG

Factor VIII Concentrates

Used according to local labeling or local treatment guidelines.

DRUG

Recombinant Activated Factor VII

Used according to local labeling or local treatment guidelines.

DRUG

Activated Prothrombin Complex Concentrate

Used according to local labeling or local treatment guidelines.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-29
Primary Completion
2026-11-01
Completion
2026-11-01
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Canada
  • Colombia
  • France
  • Germany
  • Italy
  • Japan
  • Netherlands
  • Poland
  • South Africa
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06883240 on ClinicalTrials.gov